Newer generations of MitraClip associated with greater reduction in mitral regurgitation than previous version

Source: BIBA MedTech Insights At the American College of Cardiology/World Congress of Cardiology’s virtual scientific sessions (ACC.20/WCC Virtual; 28–30 March, Chicago, USA), D Scott Lim (University of Virginia, Charlottesville, USA) reported that mitral regurgitation ≤1+ was achieved more frequently with MitraClipNTR or with MitraClipXTR (both Abbott) than previously observed with the first-generation [...]

2020-05-11T15:07:35+00:00May 11th, 2020|

COVID-19: Survey suggests increased operating days may be required to clear elective backlog

A BIBA MedTech Insights survey indicates that 50% of centres performing structural heart procedures believe that they will need to increase the number of operating days per week to manage the elective cases that have been put on hold because of COVID-19. However, 22% believe that no extra measures will be required and the backlog will [...]

2020-05-11T15:08:35+00:00May 11th, 2020|Tags: |

TAVI market changes in Q3 2019

Source: BIBA MedTech Insights TAVI Tracker The TAVI market in Western Europe grew by 19.2% between Q3 2018 and Q3 2019. Over the last three years, Edwards Lifesciences (the market leader) lost market share while Medtronic and Boston Scientific both gained market share. Boston Scientific’s acquisition of Symetis in Q2 2017 helped [...]

2020-01-21T14:46:15+00:00January 21st, 2020|Tags: , , , , , |

Sapien 3 becomes first TAVI valve to be approved for low-risk patients in both Europe and the USA

Sapien 3 Edwards Lifesciences has received the CE mark for its Sapien 3 transcatheter aortic valve implantation (TAVI) device to be used to manage aortic stenosis in low-risk patients. Both Edwards and Medtronic (with its CoreValve Evolut range) have FDA approval for their devices to be used for low-risk patients in the [...]

2020-01-03T11:58:12+00:00December 17th, 2019|Tags: , , |

Longest and largest follow-up data for Watchman supports its role in stroke prevention

Source: BIBA MedTech LAA Monitor (quarterly) Data from the CAP and CAP2 registries—which contain the longest and largest follow-up of patients—add to previous evidence that left atrial appendage closure (LAAC) with Watchman (Boston Scientific) is a safe and effective alternative to long-term anticoagulation in patients with atrial fibrillation. Furthermore, the results show [...]

2019-12-11T10:48:39+00:00December 6th, 2019|Tags: , |

Medtronic receives US FDA Breakthrough Device Designation for complex EVAR device

Source: BIBA MedTech Aortic Segmentation Monitor The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Medtronic for its novel Valiant thoracoabdominal aneurysm (TAAA) stent graft. A press release reports that the device is designed to offer an off-the-shelf solution for complex endovascular aneurysm repair (EVAR) procedures, adding that [...]

2019-10-24T08:44:10+00:00October 24th, 2019|Tags: , , , , , |

Aortic Insights Q1 2019

Source: BIBA MedTech Aortic Segmentation Monitor Aortic Insights is a quarterly report that provides in-depth analysis of the key findings of the Aortic Segmentation Monitor (BIBA MedTech Insights). Each quarter, the monitor tracks aortic procedures performed in Western Europe. It looks at the segment treated (infrarenal, complex, and thoracic), type of procedure [...]

2019-11-12T11:53:13+00:00October 8th, 2019|Tags: , |

AtriCure agrees to buy LARIAT developer SentreHEART

LARIAT AtriCure has entered into a definitive agreement to acquire SentreHEART, which developed the LARIAT device for left atrial appendage closure in patients with atrial fibrillation. A press release reports that the transaction consideration consists of an upfront payment of approximately US$40 million in cash and AtriCure common stock, plus additional contingent [...]

2019-09-16T15:38:00+00:00September 16th, 2019|Tags: , , , |

Novel repositionable TAVI valve has acceptable early clinical outcomes

Source: BIBA MedTech TAVI Monitor A new study indicates that the Meridian transcatheter aortic valve implantation (TAVI) valve (HLT) is associated with a 30-day mortality rate of 8% and a six-month mortality rate of 12%. The valve is fully retrievable after deployment, which allows an accurate assessment of valve positioning and performance [...]

2019-09-06T18:24:17+00:00September 6th, 2019|Tags: |

Poll favours interventional radiologists to perform mechanical thrombectomy in lieu of neurointerventionalists

Source: BIBA MedTech Insights According to a BIBA MedTech survey, 52% of neurointerventionalists believe that they are the only specialists who have the relevant skills and experience to perform interventional stroke procedures (e.g. mechanical thrombectomy). However, of those who believe other specialities—with the appropriate training—could potentially perform such procedures, 58% propose interventional [...]

2019-08-21T09:57:07+00:00August 20th, 2019|Tags: , , |

Edwards Lifesciences drops its self-expanding TAVI valve in favour of focusing on its balloon-expanding range

Source: BIBA MedTech TAVI Monitor Edwards Lifesciences—in a press statement announcing its global second quarter (Q2) financial results—has revealed that it is taking the self-expanding transcatheter aortic valve implantation (TAVI) device Centera off the market. The company says resources will instead be focused on the balloon-expanding Sapien range of TAVI devices, adding [...]

2019-08-09T11:01:06+00:00August 9th, 2019|Tags: , , , |

PCI Insights Q1 2019

In this edition, we review (in Market Insights) the key Q1 2019 findings of the BIBA MedTech PCI Monitor—which tracks, on a quarterly basis, the percutaneous coronary intervention (PCI) procedures performed and the coronary devices used in Western Europe. We also explore the latest news (see Technology Insights) and look at pipeline developments (go [...]

2019-12-11T10:23:38+00:00July 30th, 2019|Tags: , |
Go to Top